We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Safety and effectiveness of ruxolitinib in the real-world management of polycythemia vera patients: a collaborative retrospective study by pH-negative MPN latial group.
- Authors
Pepe, Sara; Rossi, Elena; Trawinska, Malgorzata; Tatarelli, Caterina; Di Veroli, Ambra; Maurillo, Luca; Romano, Atelda; Crescenzi, Sabrina Leonetti; di Toritto, Tommaso Caravita; Tafuri, Agostino; Latagliata, Roberto; Scalzulli, Emilia; Andriani, Alessandro; De Stefano, Valerio; Breccia, Massimo
- Abstract
Ruxolitinib is approved for polycythemia vera (PV) patients after failure to previous cytoreductive therapy, based on durable results observed in phase 3 trials. We report a multicenter retrospective study demonstrating the efficacy and safety of ruxolitinib in real-life setting. Eighty-three patients were evaluated. Median follow-up was 24.5 months (IQR 14.0–29.3). At a 3-month response assessment, ruxolitinib provided significant benefit in reducing hematocrit (HCT) level (p < 0.001), phlebotomy requirement (p < 0.001), leucocytes (p = 0.044), and disease-related symptoms (p < 0.001). The exposure-adjusted rates (per 100 patient-years) of infectious complications, thromboembolic events, and secondary malignancies were 6.9, 3, and 3.7, respectively. Non-melanoma skin cancers (NMSC) were the most frequent (40%) SM type. Lymphoproliferative disorders were not detected. Five (6%) patients permanently discontinued ruxolitinib treatment and four (5%) evolved in myelofibrosis (MF), but none in acute leukemia. The rate of MF evolution per 100 patient-years of exposure was 2.8. In our experience, ruxolitinib confirmed its efficacy and safety outside of clinical trials.
- Subjects
POLYCYTHEMIA vera; MYELOFIBROSIS; RUXOLITINIB; CLINICAL trials; LYMPHOPROLIFERATIVE disorders; RETROSPECTIVE studies
- Publication
Annals of Hematology, 2022, Vol 101, Issue 6, p1275
- ISSN
0939-5555
- Publication type
Article
- DOI
10.1007/s00277-022-04815-w